var data={"title":"Tenecteplase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tenecteplase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7064?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tenecteplase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tenecteplase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228480\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>TNKase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228481\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>TNKase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228508\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Thrombolytic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228484\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism, acute (hemodynamically unstable/massive) (off-label use): </b>IV: Administer dose as a single bolus over 5 to 10 seconds (Kline 2007; Melzer 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 to &lt;70 kg: 35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;70 to &lt;80 kg: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;80 to &lt;90 kg: 45 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;90 kg: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism, acute (hemodynamically stable/submassive) (off-label use): Note: </b>Not recommended for most patients with acute PE <i>without </i>hypotension; use only in select patients showing signs of clinical deterioration despite maintaining a systolic BP &gt;90 mm Hg where benefits outweigh risks (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Administer dose as a single bolus over 5 to 10 seconds (Kline 2007; Kline 2014; Melzer 2004; Meyer 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 to &lt;70 kg: 35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;70 to &lt;80 kg: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;80 to &lt;90 kg: 45 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;90 kg: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism associated with cardiac arrest (off-label use):</b> IV: Administer as a single bolus over 5 seconds (B&ouml;ttiger 2008; Bozeman 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 to &lt;70 kg: 35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;70 to &lt;80 kg: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;80 to &lt;90 kg: 45 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;90 kg: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>STEMI:</b> IV: The recommended total dose should not exceed 50 mg and is based on weight. Administer as a single bolus over 5 seconds:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 to &lt;70 kg: 35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;70 to &lt;80 kg: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;80 to &lt;90 kg: 45 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;90 kg: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: Thrombolytic should be administered within 30 minutes of hospital arrival.</b> Generally, there is only a small trend for benefit of therapy after a delay of 12 to 24 hours from symptom onset, but thrombolysis may be considered for selected patients with ongoing ischemic pain and extensive ST elevation; however, primary PCI is preferred in these patients. Administer concurrent aspirin, clopidogrel, and anticoagulant therapy (ie, unfractionated heparin, enoxaparin, or fondaparinux) with tenecteplase (O&rsquo;Gara 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228485\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Although dosage adjustments are not recommended, the elderly have a higher incidence of morbidity and mortality with the use of tenecteplase. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228486\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable: Unknown, but unlikely (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228487\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: No dosage adjustment provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: No dosage adjustment provided in manufacturer's labeling; weigh the risk of bleeding against the benefits with tenecteplase especially in those with a coagulopathy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228464\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TNKase: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228449\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228466\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Tenecteplase is <b>incompatible</b> with dextrose solutions. Dextrose-containing lines must be flushed with a saline solution before and after administration. Administer as a single IV bolus over 5 seconds. Avoid IM injections and nonessential handling of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>PE, acute (off-label use):</i> Administer as an IV bolus over 5 to 10 seconds using a peripheral vein (Kearon 2012; Kearon 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228465\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>ST-elevation myocardial infarction:</b> Management of ST-elevation myocardial infarction (STEMI) for the lysis of thrombi in the coronary vasculature to restore perfusion and reduce mortality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recommended criteria for treatment of STEMI (ACC/AHA [O&rsquo;Gara 2013]):</b> Ischemic symptoms within 12 hours of treatment or evidence of ongoing ischemia 12 to 24 hours after symptom onset with a large area of myocardium at risk or hemodynamic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">STEMI ECG definition: New ST-segment elevation at the J point in at least 2 contiguous leads of &ge;2 mm (0.2 mV) in men or &ge;1.5 mm (0.15 mV) in women in leads V<sub>2</sub> to V<sub>3</sub> and/or of &ge;1 mm (0.1 mV) in other contiguous precordial leads or limb leads on ECG. New or presumably new left bundle branch block (LBBB) may interfere with ST-elevation analysis and should not be considered diagnostic in isolation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">At non-PCI-capable hospitals, the ACC/AHA recommends thrombolytic therapy administration when the anticipated first medical contact (FMC)-to-device time at a PCI-capable hospital is &gt;120 minutes due to unavoidable delays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50579961\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Pulmonary embolism, acute (hemodynamically unstable/massive); Pulmonary embolism, acute (hemodynamically stable/submassive); Pulmonary embolism associated with cardiac arrest</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228516\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TNKase may be confused with Activase, t-PA</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TNK (occasional abbreviation for TNKase) is an error-prone abbreviation (mistaken as TPA or TXA, error-prone abbreviation for tranexamic acid)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228456\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (ASSENT-2 trial: minor: 22%; major: 5%), hematoma (local: minor: 12%; major: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cerebrovascular accident (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (minor: 2%; major: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Genitourinary tract hemorrhage (minor: 4%; major: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Local hemorrhage (catheter puncture site: minor: 4%; major: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngeal bleeding (minor: 3%), epistaxis (minor: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, cardiac arrhythmia, cardiac failure, cardiac tamponade, cardiogenic shock, embolism, hypotension, ischemic heart disease (recurrent), mitral valve insufficiency (regurgitation), myocardial reinfarction, myocardial rupture, pericardial effusion, pericarditis, pulmonary edema, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, intracranial hemorrhage, laryngeal edema, respiratory tract hemorrhage, retroperitoneal hemorrhage, skin rash, thrombolytic drug-induced cholesterol embolism (clinical features may include acute renal failure, bowel infarction, cerebral infarction, gangrenous digits, hypertension, livedo reticularis, myocardial infarction, pancreatitis, &ldquo;purple toe&rdquo; syndrome, retinal artery occlusion, rhabdomyolysis, spinal cord infarction), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228469\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of STEMI: Active internal bleeding; history of cerebrovascular accident; recent (ie, within 2 months) intracranial/intraspinal surgery or trauma; intracranial neoplasm; arteriovenous malformation or aneurysm; bleeding diathesis; severe uncontrolled hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional absolute contraindications</i> (ACC/AHA [O&rsquo;Gara 2013]): Ischemic stroke within 3 months; prior intracranial hemorrhage; active bleeding (excluding menses); suspected aortic dissection; significant closed head or facial trauma within 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to tenecteplase or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of PE (off-label): Structural intracranial disease, previous intracranial hemorrhage, ischemic stroke within 3 months, active bleeding, recent brain or spinal surgery, recent head trauma with fracture or brain injury, bleeding diathesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228453\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Monitor all potential bleeding sites. If serious bleeding occurs, the infusion of tenecteplase and heparin should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions that increase bleeding risk: For the following conditions, the risk of bleeding is higher with use of thrombolytics and should be weighed against the benefits of therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&bull; PE: </i>Systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg; recent bleeding (nonintracranial); recent surgery or invasive procedure; ischemic stroke &gt;3 months previously; anticoagulated (eg, VKA therapy); traumatic CPR; pericarditis or pericardial fluid; diabetic retinopathy; age &gt;75 years; low body weight (&lt;60 kg); female; black (Kearon 2012; Kearon 2016); lumbar puncture within 10 days (ASRA [Horlocker 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&bull; STEMI: </i>History of chronic, severe, poorly controlled hypertension; significant hypertension on presentation (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg); history of prior ischemic stroke &gt;3 months; dementia; traumatic or prolonged CPR (&gt;10 minutes); major surgery (&lt;3 weeks); recent internal bleeding (within 2 to 4 weeks); noncompressible vascular punctures; active peptic ulcer; oral anticoagulant therapy (ACC/AHA [O&rsquo;Gara 2013]); lumbar puncture within 10 days (ASRA [Horlocker 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. Adjunctive use of parenteral anticoagulants (eg, enoxaparin, heparin, or fondaparinux) is recommended in STEMI patients to improve vessel patency and prevent reocclusion and may also contribute to bleeding; monitor for bleeding (ACC/AHA [O&rsquo;Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age; increased risk of bleeding. The 30-day mortality in the ASSENT-2 trial of AMI patients was 2.5% for patients &lt;65 years of age, 8.5% for patients 65 to 74 years, and 16.2% for patients &ge;75 years. The intracranial hemorrhage rate was 0.4% for patients &lt;65 years, 1.6% for patients 65 to 74 years, and 1.7% for patients &ge;75 years. The risks and benefits of use should be weighed carefully in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Use with caution in pregnancy; increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Avoid intramuscular injections and nonessential handling of the patient for a few hours after administration. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed. Caution with readministration of tenecteplase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300111\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228458\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9955&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228460\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228471\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. The risk of bleeding may be increased in pregnant women. Administer to pregnant women only if the potential benefits justify the risk to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17916902\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tenecteplase is present in breast milk. The manufacturer recommends that caution be exercised when administering tenecteplase to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228462\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, aPTT, signs and symptoms of bleeding, ECG monitoring</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228452\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes initiation of fibrinolysis by binding to fibrin and converting plasminogen to plasmin. Tenecteplase is essentially alteplase with the exception of 3 point mutations and is more fibrin specific, more resistant to plasminogen activator inhibitor -1 (PAI-1), with a longer duration of action compared to alteplase. Produced by recombinant DNA technology using a mammalian cell line (Chinese hamster ovary cells).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228468\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub> is weight related and approximates plasma volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biphasic: Initial: 20 to 24 minutes; Terminal: 90 to 130 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Clearance: Plasma: 99 to 119 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613417\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (TNKase Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $7,034.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228472\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elaxim (IN);</li>\n      <li>Metalize (UA);</li>\n      <li>Metalyse (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CL, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, VN, YE, ZA, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators, &quot;Primary Versus Tenecteplase-Facilitated Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction (ASSENT-4 PCI): Randomised Trial,&quot; <i>Lancet</i>, 2006, 367(9510):569-78.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19092151\"></a>B&ouml;ttiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. <i>N Engl J Med</i>. 2008;359(25):2651-2662.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/19092151/pubmed\" target=\"_blank\" id=\"19092151\">19092151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16563599\"></a>Bozeman WP, Kleiner DM, Ferguson KL. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. <i>Resuscitation</i>. 2006;69(3):399-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/16563599/pubmed\" target=\"_blank\" id=\"16563599\">16563599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cannon CP, Gibson CM, McCabe CH, et al. &ldquo;TNK-Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. Results of the TIMI 10B Trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators,&rdquo; <i>Circulation</i>, 1998, 98(25):2805-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/9860780/pubmed\" target=\"_blank\" id=\"9860780\">9860780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Luca G, Suryapranata H, Stone GW, et al, &ldquo;Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials,&rdquo; <i>JAMA</i>, 2005, 293(14):1759-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/15827315/pubmed\" target=\"_blank\" id=\"15827315\">15827315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators,&rdquo; <i>Lancet</i>, 2001, 358(9282):605-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/11530146/pubmed\" target=\"_blank\" id=\"11530146\">11530146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). <i>Reg Anesth Pain Med</i>. 2010;35(1):64-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/20052816/pubmed\" target=\"_blank\" id=\"20052816\">20052816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kline JA, Hernandez-Nino J, Jones AE. Tenecteplase to treat pulmonary embolism in the emergency department. <i>J Thromb Thrombolysis</i>. 2007;23(2):101-105. doi: 10.1007/s11239-006-9018-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/17221330/pubmed\" target=\"_blank\" id=\"17221330\">17221330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. <i>J Thromb Haemost</i>. 2014;12(4):459-468. doi: 10.1111/jth.12521.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/24484241/pubmed\" target=\"_blank\" id=\"24484241\">24484241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keeley EC, Boura JA, and Grines CL, &quot;Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-Elevation Myocardial Infarction: Quantitative Review of Randomised Trials,&quot; <i>Lancet</i>, 2006, 367(9510):579-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/16488801/pubmed\" target=\"_blank\" id=\"16488801\">16488801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26472998\"></a>Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(18 Suppl 2):S501-518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/26472998/pubmed\" target=\"_blank\" id=\"26472998\">26472998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Melzer C, Richter C, Rogalla P, et al. Tenecteplase for the treatment of massive and submassive pulmonary embolism. <i>J Thromb Thrombolysis</i>. 2004;18(1):47-50. doi: 10.1007/s11239-004-0174-z.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/15744554/pubmed\" target=\"_blank\" id=\"15744554\">15744554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. <i>N Engl J Med</i>. 2014;370(15):1402-1141. doi: 10.1056/NEJMoa1302097.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/24716681/pubmed\" target=\"_blank\" id=\"24716681\">24716681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25873823\"></a>Nobre C, Thomas B, Santos L, Tavares J. Prolonged chest compressions during cardiopulmonary resuscitation for in-hospital cardiac arrest due to acute pulmonary embolism. <i>Tex Heart Inst J</i>. 2015;42(2):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/25873823/pubmed\" target=\"_blank\" id=\"25873823\">25873823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor RE, Brady W, Brooks SC, et al, &ldquo;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/20956226/pubmed\" target=\"_blank\" id=\"20956226\">20956226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACC/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parsons M, Miteff F, Bateman GA, et al, &ldquo;Acute Ischemic Stroke: Imaging-Guided Tenecteplase Treatment in an Extended Time Window,&rdquo; <i>Neurology</i>, 2009, 72(10):915-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/19273826/pubmed\" target=\"_blank\" id=\"19273826\">19273826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parsons M, Spratt N, Bivard A, et al, &ldquo;A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke,&rdquo; <i>N Engl J Med</i>, 2012, 366(12):1099-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/22435369/pubmed\" target=\"_blank\" id=\"22435369\">22435369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21119096\"></a>Perrott J, Henneberry RJ, Zed PJ. Thrombolytics for cardiac arrest: case report and systematic review of controlled trials. <i>Ann Pharmacother</i>. 2010;44(12):2007-2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/21119096/pubmed\" target=\"_blank\" id=\"21119096\">21119096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Single-Bolus Tenecteplase Compared With Front-Loaded Alteplase in Acute Myocardial Infarction: The ASSENT-2 Double-blind Randomised Trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators,&rdquo; <i>Lancet</i>, 1999, 354(9180):716-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/10475182/pubmed\" target=\"_blank\" id=\"10475182\">10475182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinnaeve PR, Alexander JH, Bogaerts K, et al, &quot;Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,&quot; <i>Am Heart J</i>, 2004, 147:993-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/15199346/pubmed\" target=\"_blank\" id=\"15199346\">15199346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TNKase (tenecteplase) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; May 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol EJ, GUSTO V Investigators, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,&rdquo; <i>Lancet</i>, 2001, 357:1905-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/11425410/pubmed\" target=\"_blank\" id=\"11425410\">11425410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van de Werf F, Cannon CP, Luyten A, et al, &ldquo;Safety Assessment of a Single-Bolus Administration of TNK Tissue-Plasminogen Activator in Acute Myocardial Infarction: The ASSENT-1 Trial. The ASSENT-1 Investigators,&rdquo; <i>Am Heart J</i>, 1999, 137(5):786-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/10220625/pubmed\" target=\"_blank\" id=\"10220625\">10220625</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9955 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F228480\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F228481\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F228508\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F228484\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F228485\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F228486\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F228487\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F228464\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F228449\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F228466\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F228465\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50579961\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F228516\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F228456\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F228469\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F228453\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300111\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F228458\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F228460\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F228471\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17916902\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F228462\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F228452\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F228468\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613417\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F228472\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9955|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tenecteplase-patient-drug-information\" class=\"drug drug_patient\">Tenecteplase: Patient drug information</a></li></ul></div></div>","javascript":null}